Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADX 71149

Drug Profile

ADX 71149

Alternative Names: ADX-71149; JNJ-40411813; JNJ-mGluR2-PAM

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics; Janssen Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Anxiolytics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Preclinical Panic disorder
  • Discontinued Major depressive disorder; Psychiatric disorders; Schizophrenia

Most Recent Events

  • 04 Sep 2018 Preclinical trials in Panic disorder in Switzerland (PO) before September 2018
  • 24 Jun 2018 Biomarkers information updated
  • 27 Feb 2017 Addex Therapeutics and Janssen Pharmaceuticals plan a phase IIa proof of concept trial for Epilepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top